It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Human glioblastoma (GBM) is the most common primary malignant brain tumor. A minor subpopulation of cancer cells, known as glioma stem-like cells (GSCs), are thought to play a major role in tumor relapse due to their stem cell-like properties, their high resistance to conventional treatments and their high invasion capacity. We show that ionizing radiation specifically enhances the motility and invasiveness of human GSCs through the stabilization and nuclear accumulation of the hypoxia-inducible factor 1α (HIF1α), which in turn transcriptionally activates the Junction-mediating and regulatory protein (JMY). Finally, JMY accumulates in the cytoplasm where it stimulates GSC migration via its actin nucleation-promoting activity. Targeting JMY could thus open the way to the development of new therapeutic strategies to improve the efficacy of radiotherapy and prevent glioma recurrence.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Gitton-Quent Oscar 1 ; Romane, Bertrand 3 ; Busso Didier 1 ; Marc-André, Mouthon 1
; Collura Ada 3
; Marie-Pierre, Junier 4 ; Chneiweiss Hervé 4
; Pineda, José R 5
; Boussin, François D 1 1 UMR Stabilité Génétique Cellules Souches et Radiations, Université de Paris and Université Paris-Saclay, Inserm, LRP/iRCM/IBFJ CEA, Fontenay-aux-Roses, France (GRID:grid.7429.8) (ISNI:0000000121866389)
2 UMR Stabilité Génétique Cellules Souches et Radiations, Université de Paris and Université Paris-Saclay, Inserm, LRP/iRCM/IBFJ CEA, Fontenay-aux-Roses, France (GRID:grid.7429.8) (ISNI:0000000121866389); Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, Inserm U861, I-Stem, CECS, UEVE, AFM, Corbeil-Essonnes, France (GRID:grid.8390.2) (ISNI:0000 0001 2180 5818)
3 Centre de Recherche Saint Antoine, Sorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, Equipe Instabilité des Microsatellites et Cancer, Paris, France (GRID:grid.465261.2) (ISNI:0000 0004 1793 5929)
4 Sorbonne Universités, CNRS UMR8246, Inserm U1130, Neuroscience Paris Seine-IBPS, UPMC, Paris, France (GRID:grid.462844.8) (ISNI:0000 0001 2308 1657)
5 UMR Stabilité Génétique Cellules Souches et Radiations, Université de Paris and Université Paris-Saclay, Inserm, LRP/iRCM/IBFJ CEA, Fontenay-aux-Roses, France (GRID:grid.7429.8) (ISNI:0000000121866389); Achucarro Basque Center for Neuroscience, Leioa, Spain (GRID:grid.427629.c)




